Cocrystal Pharma filed an IND to proceed with US clinical trials, while the CDC estimated 685 million annual Norovirus cases.
2 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cocrystal Pharma filed an IND to proceed with US clinical trials, while the CDC estimated 685 million annual Norovirus cases.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Cocrystal Pharma
company in Bothell, United States
Nothing else this week.
-
Centers for Disease Control
governmental medical research institute with headquarters in Taipei, Taiwan
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
Coverage
Newest first; wire copies grouped- Zacks Small Cap ResearchCOCP: Norovirus Challenge Study to Initiate in 4Q25… By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Norovirus Challenge Study to Commence in 4Q25 Cocrystal Pharma,
- GlobeNewswireCocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIR